Orstanorm (Dihydroergotamine Mesilate)

Dihydroergotamine mesilate, the active ingredient in Orstanorm, is an ergot alkaloid presented as a tablet for oral use. It is employed to treat acute migraine attacks and, off‑label, cluster headaches in adult patients, providing rapid relief of severe headache symptoms.

GNH USA supplies Orstanorm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with consistent quality and regulatory compliance.

Orstanorm acts on the serotonergic and vascular pathways involved in primary headache disorders.

Acute migraine attacks: provides rapid relief of migraine pain and associated symptoms. Cluster headache (off‑label): may reduce the frequency and intensity of cluster headache episodes. Migraine with aura: helps abort the headache phase in patients experiencing visual or sensory aura preceding migraine.

Orstanorm may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea - Vomiting - Dizziness or light‑headedness - Fatigue or weakness - Chest tightness or discomfort - Peripheral coldness or tingling

Serious or Rare Side Effects: - Severe hypertension or hypertensive crisis - Myocardial ischemia or infarction - Cerebrovascular events such as stroke - Anaphylactic or severe allergic reactions - Serotonin syndrome when combined with serotonergic agents - Severe vasospasm leading to tissue necrosis

When prescribing Orstanorm, consider the following precautions to ensure safe use.

Assess cardiovascular status: evaluate for hypertension, coronary artery disease, or peripheral vascular disease before initiating therapy. Avoid in uncontrolled hypertension: risk of severe vasoconstriction and hypertensive crisis. Caution in cerebrovascular disease: potential to precipitate stroke. Monitor for serotonin syndrome: especially when used with SSRIs, SNRIs, or triptans. Store at ambient temperature: keep in the original packaging, protect from moisture.

Orstanorm can interact with several medicines; awareness of the interaction level helps manage risk.

Major Interactions (Avoid): - Other ergotamine‑containing products: additive vasoconstriction. - Potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increased plasma concentrations. - Serotonergic agents (SSRIs, SNRIs, triptans): heightened risk of serotonin syndrome. - MAO inhibitors: amplified vasoconstrictive effects.

Moderate Interactions (Monitor Closely): - Antihypertensive drugs: possible reduction in blood‑pressure control. - Beta‑blockers: may enhance bradycardia or hypotensive effects.